News

Filter

Current filters:

EisaiEurope

Eisai’s Zonegran safety in pediatric patients confirmed by pooled data analysis

Eisai’s Zonegran safety in pediatric patients confirmed by pooled data analysis

10-11-2014

The safety profile of adjunctive Japanese drugmaker Eisai’s Zonegran (zonisamide) in pediatric patients…

EisaiEuropeNeurologicalPharmaceuticalResearchZonegran

Eisai files for US and EU approval of lenvatinib for hard to treat thyroid cancer

Eisai files for US and EU approval of lenvatinib for hard to treat thyroid cancer

18-08-2014

Japanese pharma major Eisai has filed applications with the US Food and Drug Administration and the European…

DonepezilEisaiEuropelenvatinibOncologyPharmaceuticalRegulationUSA

EMA approves Eisai's request for accelerated assessment of lenvatinib in thyroid cancer

EMA approves Eisai's request for accelerated assessment of lenvatinib in thyroid cancer

31-07-2014

The European Medicines Agency (EMA) has approved a request by Japanese drug major Eisai for the accelerated…

Cell signalingEisaiEuropeEuropean Medicines AgencylenvatinibOncologyPharmaceuticalRegulationThyroid cancer

Eisai’s breast cancer drug Halaven receives MAA in Europe

Eisai’s breast cancer drug Halaven receives MAA in Europe

03-07-2014

The European Commission has issued Marketing Authorization Approval (MAA) for Halaven (eribulin) from…

EisaiEuropeHalavenOncologyPharmaceuticalRegulation

Eisai’s Zebinix shown to be effective and well-tolerated

Eisai’s Zebinix shown to be effective and well-tolerated

30-06-2014

Once-daily Zebinix (eslicarbazepine acetate) from Japanese drug major Eisai is effective, retained and…

EisaiEuropeNeurologicalPharmaceuticalResearchZebinix

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

22-01-2014

The investigational monoclonal antibody amatuximab (development code: MORAb-009), has today been granted…

amatuximabEisaiEuropePharmaceuticalRare diseasesRegulation

Back to top